Precigen's treatment has started in over 500 patients for a disease long managed by repeated surgery
The company reports growing uptake of its therapy for recurrent respiratory papillomatosis.
Read at Stock Titan →Full coverage · 5 outlets
- Stock Titan · lead
- BenzingaPrecigen Q3 2026 Earnings Call Transcript
- Seeking AlphaPrecigen: Has To Grow Into Its Valuation
- PR NewswirePrecigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
- YahooPrecigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance